 |
TSO3: Another American healthcare system acquires a 125L Ozone SterilizerNovember 16, 2007Québec City, November 16, 2007 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces another sale of its 125L Ozone Sterilizer to an American healthcare system.“The message from hospital decision makers is consistent: they are seeking a product that is easy to use, economical and completely safe for the users, the patients and increasingly, the environment,” said Ann Hewitt, VP Sales & Marketing for TSO3 Inc. “To date, we estimate that over 100,000 patients throughout North America have had surgery with instruments which were sterilized in a TSO3 ozone sterilizer.” This most recent sale was made to a healthcare system which is the largest, most comprehensive, non-profit health provider in its area. “Our sales force is complete for this year. Our focus right now is entirely on closing more business before year end”, stated Jocelyn Vézina, CEO for TSO3 Inc. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology whit high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. TSO3 currently has more than 72 employees, about half of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications & IR (418) 651-0003, Ext. 237 Email: ccote@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
